Frankfurt - Delayed Quote EUR
Cellectar Biosciences, Inc. (NV4.F)
0.2480
+0.0020
+(0.81%)
At close: April 25 at 3:49:30 PM GMT+2
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 3 | 4 |
| Avg. Estimate | -- | -- | -- | 31.1M |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | 124.4M |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | 0.00% | 0.00% | 0.00% | 0.00% |
EPS Trend
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| NV4.F | -- | -- | -- | -- |
| S&P 500 | 9.62% | 4.20% | 8.36% | 13.90% |
Upgrades & Downgrades
| Downgrade | Oppenheimer: Outperform to Perform | 12/11/2024 |
| Maintains | Oppenheimer: Outperform to Outperform | 11/19/2024 |
| Maintains | Roth MKM: Buy to Buy | 3/28/2024 |
| Reiterates | Oppenheimer: Outperform to Outperform | 3/28/2024 |
| Reiterates | Roth MKM: Buy to Buy | 3/4/2024 |
| Maintains | HC Wainwright & Co.: Buy | 11/4/2022 |